TR200401007T4 - Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları - Google Patents

Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları

Info

Publication number
TR200401007T4
TR200401007T4 TR2004/01007T TR200401007T TR200401007T4 TR 200401007 T4 TR200401007 T4 TR 200401007T4 TR 2004/01007 T TR2004/01007 T TR 2004/01007T TR 200401007 T TR200401007 T TR 200401007T TR 200401007 T4 TR200401007 T4 TR 200401007T4
Authority
TR
Turkey
Prior art keywords
alpha
formula
carbamates
receptor agonists
acetylcholine receptor
Prior art date
Application number
TR2004/01007T
Other languages
English (en)
Turkish (tr)
Inventor
Nozulak Joachim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200401007T4 publication Critical patent/TR200401007T4/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TR2004/01007T 2000-05-05 2001-05-03 Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları TR200401007T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds

Publications (1)

Publication Number Publication Date
TR200401007T4 true TR200401007T4 (tr) 2004-07-21

Family

ID=9891092

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01007T TR200401007T4 (tr) 2000-05-05 2001-05-03 Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları

Country Status (29)

Country Link
US (1) US6780861B2 (enExample)
EP (1) EP1282620B1 (enExample)
JP (1) JP4898062B2 (enExample)
KR (1) KR20020093974A (enExample)
CN (1) CN1167703C (enExample)
AR (1) AR028073A1 (enExample)
AT (1) ATE263167T1 (enExample)
AU (2) AU2001262257B2 (enExample)
BR (1) BR0110521A (enExample)
CA (1) CA2407972C (enExample)
CZ (1) CZ20023622A3 (enExample)
DE (1) DE60102581T2 (enExample)
DK (1) DK1282620T3 (enExample)
ES (1) ES2218418T3 (enExample)
GB (1) GB0010955D0 (enExample)
HK (1) HK1054223B (enExample)
HU (1) HUP0301866A2 (enExample)
IL (1) IL152417A0 (enExample)
MX (1) MXPA02010892A (enExample)
NO (1) NO20025280D0 (enExample)
NZ (1) NZ522226A (enExample)
PE (1) PE20020221A1 (enExample)
PL (1) PL357435A1 (enExample)
PT (1) PT1282620E (enExample)
RU (1) RU2002131886A (enExample)
SK (1) SK15612002A3 (enExample)
TR (1) TR200401007T4 (enExample)
WO (1) WO2001085727A1 (enExample)
ZA (1) ZA200208969B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
BR0213501A (pt) * 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) * 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
CN1735414A (zh) 2002-12-06 2006-02-15 北岸长岛犹太人研究学院 用α7受体结合类胆碱激动剂抑制炎症
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
MXPA05010496A (es) * 2003-03-28 2005-11-16 Pharmacia & Upjohn Co Llc Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
WO2005063767A2 (en) * 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
EP1713809B1 (en) 2004-02-04 2009-07-29 Neurosearch A/S Dimeric azacyclic compounds and their use
US20050234095A1 (en) 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、1h−インダゾール、1,2−ベンズイソキサゾール、1,2−ベンゾイソチアゾール、ならびにその調製および使用
US7632831B2 (en) * 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
RU2418797C2 (ru) * 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
ES2541528T3 (es) 2008-11-19 2015-07-21 Forum Pharmaceuticals Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2010132423A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US20120157464A1 (en) * 2009-07-23 2012-06-21 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
JP5852094B2 (ja) * 2010-03-26 2016-02-03 コーニング インコーポレイテッド 低非線形長距離用光通信システム
JP5749797B2 (ja) 2010-05-17 2015-07-15 フォルム ファーマシューティカルズ、インコーポレイテッド (r)−7−クロロ−n−(キヌクリジン−3−イル)ベンゾ[b]チオフェン−2−カルボキサミド塩酸塩一水和物の結晶形
RU2013108223A (ru) 2010-07-26 2014-09-10 Энвиво Фармасьютикалз, Инк. Лечение когнитивных нарушений определенными агонистами рецептора никотиновой кислоты альфа-7 в сочетании с ингибиторами ацетилхолинэстеразы
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
UA118248C2 (uk) * 2011-03-18 2018-12-26 Джензім Корпорейшн Інгібітори глюкозилцерамідсинтази
US20140228398A1 (en) 2011-03-18 2014-08-14 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
CN103502213B (zh) * 2011-04-29 2016-09-28 奇斯药制品公司 生物碱酯及其氨基甲酸酯衍生物和医学组合物
BR112014007485B1 (pt) * 2011-10-20 2022-05-31 Novartis Ag Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN104837499B (zh) 2012-12-11 2018-02-23 诺华有限公司 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物
CA2898080C (en) 2013-01-15 2018-01-09 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
JP6137336B2 (ja) * 2013-01-15 2017-05-31 ノバルティス アーゲー ナルコレプシーの処置のためのアルファ7ニコチン性受容体アゴニストの使用
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US12083115B2 (en) 2020-02-03 2024-09-10 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1996008468A1 (en) * 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6313247B1 (en) * 1996-06-05 2001-11-06 Wolfgang Lindner Cinchonan based chiral selectors for separation of stereoisomers
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser
AU782114B2 (en) * 1999-09-28 2005-07-07 Eisai R&D Management Co., Ltd. Quinuclidine compounds and drugs containing the same as the active ingredient
WO2002016358A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Also Published As

Publication number Publication date
CZ20023622A3 (cs) 2003-02-12
PT1282620E (pt) 2004-07-30
ATE263167T1 (de) 2004-04-15
DE60102581D1 (de) 2004-05-06
DE60102581T2 (de) 2005-02-03
AU6225701A (en) 2001-11-20
NO20025280L (no) 2002-11-04
HK1054223A1 (en) 2003-11-21
US6780861B2 (en) 2004-08-24
AR028073A1 (es) 2003-04-23
WO2001085727A1 (en) 2001-11-15
JP2003532731A (ja) 2003-11-05
GB0010955D0 (en) 2000-06-28
AU2001262257B2 (en) 2004-11-04
NZ522226A (en) 2004-08-27
ZA200208969B (en) 2003-10-07
HK1054223B (en) 2005-03-04
HUP0301866A2 (hu) 2003-09-29
ES2218418T3 (es) 2004-11-16
CN1167703C (zh) 2004-09-22
EP1282620A1 (en) 2003-02-12
DK1282620T3 (da) 2004-07-19
CA2407972C (en) 2010-03-09
US20030166654A1 (en) 2003-09-04
CA2407972A1 (en) 2001-11-15
RU2002131886A (ru) 2004-04-10
PL357435A1 (en) 2004-07-26
JP4898062B2 (ja) 2012-03-14
EP1282620B1 (en) 2004-03-31
BR0110521A (pt) 2003-04-08
SK15612002A3 (sk) 2003-04-01
PE20020221A1 (es) 2002-04-23
CN1427840A (zh) 2003-07-02
NO20025280D0 (no) 2002-11-04
MXPA02010892A (es) 2003-03-27
IL152417A0 (en) 2003-05-29
KR20020093974A (ko) 2002-12-16

Similar Documents

Publication Publication Date Title
TR200401007T4 (tr) Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları
ATE203524T1 (de) Chinazolin-derivate
DE60033857D1 (de) Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
CA2272291A1 (en) Crf antagonistic quino- and quinazolines
WO1999042465A3 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
MXPA02012425A (es) Compuestos nuevos.
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
ATE277889T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
PE20010638A1 (es) Imidazo-5-il-aminas biciclicas, medicamentos que las contienen, su uso para la preparacion de medicamentos y procedimiento para su preparacion
MXPA04003008A (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa 13 de la matriz.
NZ528997A (en) Sulfonamides
ID23954A (id) Tetrahidrogama-karbolin
ES8307244A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.
FR2798126B1 (fr) Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
RU2396264C2 (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора
DK0925295T3 (da) Derivater af N-benzensulfonyl-L-prolin som antagonister af receptoren B2 for bradykinin
NZ337749A (en) Benzimidazole derivative and their use in allergy-related disease
DK0732332T3 (da) Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
MY118312A (en) Angiogenesis inhibiting 5- substituted- 1,2,4- thiadiazolyl derivatives
AR020294A1 (es) COMPUESTOS DERIVADOS DE 1-TRIFLUOROMETIL-4-HIDROXI-7-PIPERIDINIL-AMINOMETILCROMANO, COMPOSICION FARMACEUTICA Y USO EN LA PREPARACIoN DE MEDICAMENTOS.
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.
DE69732359D1 (de) Disubstituierte morpholin-, oxazepin- oder thiazepinderivate, deren herstellung und verwendung als dopamin-d4-rezeptorantagonisten
DE69521895D1 (de) Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten